Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$469.71
-0.97 (-0.21%)
(As of 07/26/2024 ET)
Today's Range
$467.80
$476.23
50-Day Range
$468.20
$530.07
52-Week Range
$372.50
$583.39
Volume
588,413 shs
Average Volume
476,837 shs
Market Capitalization
$38.79 billion
P/E Ratio
45.47
Dividend Yield
N/A
Price Target
$585.89

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
24.7% Upside
$585.89 Price Target
Short Interest
Healthy
3.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.64mentions of IDEXX Laboratories in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$108,160 Sold Last Quarter
Proj. Earnings Growth
13.45%
From $11.00 to $12.48 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.28 out of 5 stars

Medical Sector

155th out of 936 stocks

Diagnostic Substances Industry

4th out of 15 stocks

IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

IDEXX Laboratories (NASDAQ:IDXX) Coverage Initiated at BTIG Research
Analyst Ratings For IDEXX Laboratories
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
NC city lands 275-job manufacturing plant from IDEXX
IDXX Dec 2024 440.000 call
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
IDXX Aug 2024 260.000 put (IDXX240816P00260000)
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$585.89
High Stock Price Target
$650.00
Low Stock Price Target
$510.00
Potential Upside/Downside
+24.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
29.24%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$11.52 per share
Book Value
$17.88 per share

Miscellaneous

Free Float
80,844,000
Market Cap
$38.79 billion
Optionable
Optionable
Beta
1.32

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

IDXX Stock Analysis - Frequently Asked Questions

How have IDXX shares performed this year?

IDEXX Laboratories' stock was trading at $555.05 at the beginning of the year. Since then, IDXX stock has decreased by 15.4% and is now trading at $469.71.
View the best growth stocks for 2024 here
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Wednesday, May, 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.13. The firm had revenue of $964.10 million for the quarter, compared to analysts' expectations of $965.43 million. IDEXX Laboratories had a trailing twelve-month return on equity of 63.66% and a net margin of 23.26%.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

Who are IDEXX Laboratories' major shareholders?

Top institutional shareholders of IDEXX Laboratories include Bank of New York Mellon Corp (0.75%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), LGT Capital Partners LTD. (0.19%) and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, James F Polewaczyk, Kathy V Turner, George Fennell, Michael Lane, Daniel M Junius, M Anne Szostak, Sophie V Vandebroek, Bruce L Claflin, Nimrata Hunt and Giovani Twigge.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA) and Alibaba Group (BABA).

This page (NASDAQ:IDXX) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners